<span item_type="fundamental" item_id="1acfd3f870a8de8b2d9ce45d9659977f" counter_id="ST/US/PMCB" env="prod"></span><span item_type="announcement" item_id="595132738027001089" env="prod"></span><p>Revenue: As of FY2026 Q2, the actual value is USD 0.</p><p>EPS: As of FY2026 Q2, the actual value is USD -1.24.</p><p>EBIT: As of FY2026 Q2, the actual value is USD -1.582 M.</p><p></p><h3>Operational Metrics</h3><ul><li><strong>Net Income (Loss)</strong>: For the three months ended October 31, 2025, the net loss was - $7,417,975 compared to - $1,469,560 for the same period in 2024. For the six months ended October 31, 2025, the net loss was - $15,778,071 compared to a net income of $21,951,795 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1157075/000168316825009259/pharmacyte_i10q-103125.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Operating Cash Flow</strong>: Net cash used in operating activities was - $2,973,504 for the six months ended October 31, 2025, compared to - $1,428,032 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1157075/000168316825009259/pharmacyte_i10q-103125.htm"></span></li><li><strong>Investing Cash Flow</strong>: Net cash used in investing activities was - $3,000,000 for the six months ended October 31, 2025, compared to - $7,000,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1157075/000168316825009259/pharmacyte_i10q-103125.htm"></span></li><li><strong>Financing Cash Flow</strong>: Net cash provided by financing activities was $6,207,616 for the six months ended October 31, 2025, compared to net cash used of - $20,912,124 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1157075/000168316825009259/pharmacyte_i10q-103125.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Convertible Note Receivable - Femasys</strong>: The fair value of the Femasys Note was $5,000,000 as of October 31, 2025, and was settled in full in cash in November 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1157075/000168316825009259/pharmacyte_i10q-103125.htm"></span></li><li><strong>Investment in Preferred Stock - QCLS</strong>: The fair value of the Series G Preferred Stock was $15,914,000 as of October 31, 2025, down from $22,474,000 as of April 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1157075/000168316825009259/pharmacyte_i10q-103125.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company is focused on addressing the FDA’s clinical hold on its Investigational New Drug Application for a planned clinical trial in locally advanced, inoperable pancreatic cancer. The company is conducting additional studies and gathering information to submit to the FDA.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1157075/000168316825009259/pharmacyte_i10q-103125.htm"></span></li><li><strong>Non-Core Business</strong>: The company is reviewing its relationship with SG Austria and considering a new framework for collaboration. This review may impact the company’s development programs dependent on SG Austria.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1157075/000168316825009259/pharmacyte_i10q-103125.htm"></span></li></ul><h3>Priority</h3><ul><li>The company expects to need additional capital to complete a clinical trial for the treatment of pancreatic cancer. It is exploring options for equity financing, debt financing, and collaborative or licensing arrangements.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1157075/000168316825009259/pharmacyte_i10q-103125.htm"></span></li></ul>

PharmaCyte Biotech | 10-Q: FY2026 Q2 Revenue: USD 0